Prof Kenneth Anderson chairs a discussion on novel immunotherapies for treating multiple myeloma

12 May 2015 Oncology

Dr Keith Stewart chairs a discussion on tumour biology-guided treatment for multiple myeloma

12 May 2015 Hematology

Clinical significance of progenitor cells in multiple myeloma

12 May 2015 Hematology

An update on the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey

12 May 2015 Oncology

PALOMA-1 study of palbociclib in ER+, HER2-, breast cancer

12 May 2015 Oncology

The importance of the St. Gallen Breast Cancer Conference

12 May 2015 Oncology

An update in breast cancer management at St. Gallen 2015

24 Apr 2015 Oncology

Targeting BCL-2 for treating oestrogen-positive breast cancer

24 Apr 2015 Oncology

Highlights from the St. Gallen Breast Cancer Conference 2015

24 Apr 2015 Oncology

The current biosimilar landscape

24 Apr 2015 Oncology

Biosimilars for breast cancer treatment

24 Apr 2015 Oncology

CDK 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer

24 Apr 2015 Oncology

Ki67 as a marker for making management decisions in breast cancer

24 Apr 2015 Oncology

New drugs in neoadjuvant breast cancer therapy

24 Apr 2015 Oncology

Are randomised trials obsolete or more important than ever?

24 Apr 2015 Oncology

An Interview with Prof. Dmitry Pushkar at EAU 2015

14 Apr 2015 Oncology

Immune pathways and immunome as targets for breast cancer treatment

14 Apr 2015 Oncology

Personalised breast cancer treatment

14 Apr 2015 Oncology

ESMO 2014: The collaboration between basic scientists and clinicians

20 Mar 2015 Oncology

ESMO 2014: The TRACERx study of lung cancer

20 Mar 2015 Oncology

ESMO 2014: Tumour evolution and precision medicine

20 Mar 2015 Oncology

ESMO 2014: Tumour evolution and proactive clinical management

20 Mar 2015 Oncology

ESMO 2014: The collaboration between UCL and the Francis Crick Institute

16 Mar 2015 Oncology

ESMO 2014: Inhibition of PARP, angiogenesis and immune checkpoints for ovarian cancer management

16 Mar 2015 Oncology

ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma

17 Feb 2015 Oncology

Prof John Gribben and Prof Andre Goy at ASH 2014: Treating mantle cell lymphoma (Part 3)

17 Feb 2015 Hematology

ASH 2014: Recent investigational advances in mantle cell lymphoma treatment

17 Feb 2015 Hematology

ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)

17 Feb 2015 Hematology